Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus OGESTREL 0 5 50 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus OGESTREL 0 5 50 21.
NORTREL 0.5/35-28 vs OGESTREL 0.5/50-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone and ethinyl estradiol are a combination hormonal contraceptive. Norethindrone suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and enhances the contraceptive effect by inhibiting gonadotropin secretion.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
1 tablet orally once daily for 28 days (21 active tablets containing 0.5 mg norethindrone and 35 mcg ethinyl estradiol, followed by 7 placebo tablets).
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Norethindrone: 7.2-9.2 hours; Ethinyl estradiol: 13-27 hours. Clinical context: Steady state reached in 5-7 days; half-life supports once-daily dosing.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites; <5% unchanged.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive